Darlene Dobkowski | Authors


Venetoclax/Rituximab Shows 5-Year Survival Benefit in Relapsed/Refractory CLL

December 05, 2020

Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.